Literature DB >> 31742035

Correlation Between Superoxide Dismutase Serum Level Alteration with Neck Metastatic Tumor Post Cisplatin-Paclitaxel Chemotherapy Response in Nasopharyngeal Carcinoma Patients.

Achmad Chusnu Rhomdhoni1, Puji Kurniawan1, Titiek Hidayati1.   

Abstract

Nasopharyngeal carcinoma (NPC) is a malignant tumor in the nasopharynx. The patients treated with neoadjuvan combination chemotherapy cisplatin-paclitaxel while waiting a radiotherapy. This combination can produce a very high reactive oxygen species (ROS) level. Our body has a protective mechanism against oxidant through superoxide dismutase (SOD) that can inhibit DNA chain damage from ROS induction produced by chemotherapy in NPC patients. This study aimed to analyze the correlation between SOD level alteration with neck metastatic tumor response after cisplatin-paclitaxel chemotherapy. This was a cohort study. Thirty samples examined for neck metastasis tumor volume (VTM) and serum SOD were examined with ELISA pre- and postchemotherapy. Statistical significance was defined as p < 0.05. Mean SOD serum level pre-chemotherapy and post-chemotherapy were was 179.5 and 209.1, respectively. Mean tumor metastaic volume pre and post chemotherapy were 127.3 and 62.7, respectively. The correlation test with the result (r) 0.180 and p = 0.340. There was no correlation between SOD serum level alteration with VTM volume post cisplatin-paclitaxel chemotherapy in NPC patients. © Association of Otolaryngologists of India 2018.

Entities:  

Keywords:  Cisplatin–paclitaxel chemotherapy; Metastasic tumor; Nasopharyngeal carcinoma; Superoxide dismutase

Year:  2018        PMID: 31742035      PMCID: PMC6848335          DOI: 10.1007/s12070-018-1452-y

Source DB:  PubMed          Journal:  Indian J Otolaryngol Head Neck Surg        ISSN: 2231-3796


  7 in total

Review 1.  Adjuvant chemotherapy in head and neck cancer.

Authors:  S S Agarwala
Journal:  Hematol Oncol Clin North Am       Date:  1999-08       Impact factor: 3.722

2.  Oxidant/antioxidant parameters and their relationship with chemotherapy in Hodgkin's lymphoma.

Authors:  E Kaya; L Keskin; I Aydogdu; I Kuku; N Bayraktar; M A Erkut
Journal:  J Int Med Res       Date:  2005 Nov-Dec       Impact factor: 1.671

Review 3.  Concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a treatment paradigm also applicable to patients in Southeast Asia.

Authors:  Heming Lu; Luxing Peng; Xianbin Yuan; Yanrong Hao; Zhiping Lu; Jiaxin Chen; Jinjian Cheng; Shan Deng; Junzhao Gu; Qiang Pang; Jian Qin
Journal:  Cancer Treat Rev       Date:  2009-02-10       Impact factor: 12.111

4.  Nasopharyngeal cancer: impact of skull base invasion on patients prognosis and its potential implications on TNM staging.

Authors:  Yi-Zhuo Li; Pei-Qiang Cai; Chuan-Miao Xie; Zi-Lin Huang; Guo-Yi Zhang; Yao-Pan Wu; Li-Zhi Liu; Ci-Yong Lu; Rui Zhong; Pei-Hong Wu
Journal:  Eur J Radiol       Date:  2012-11-20       Impact factor: 3.528

5.  Mitochondrial dysfunction in hearing loss.

Authors:  Nathan Fischel-Ghodsian; Richard D Kopke; Xianxi Ge
Journal:  Mitochondrion       Date:  2004-11-06       Impact factor: 4.160

Review 6.  Mechanisms of Cisplatin nephrotoxicity.

Authors:  Ronald P Miller; Raghu K Tadagavadi; Ganesan Ramesh; William Brian Reeves
Journal:  Toxins (Basel)       Date:  2010-10-26       Impact factor: 4.546

Review 7.  Nasopharyngeal carcinoma.

Authors:  Bernadette Brennan
Journal:  Orphanet J Rare Dis       Date:  2006-06-26       Impact factor: 4.123

  7 in total
  1 in total

1.  Research status and prospects of biomarkers for nasopharyngeal carcinoma in the era of high‑throughput omics (Review).

Authors:  Shan-Qiang Zhang; Su-Ming Pan; Si-Xian Liang; Yu-Shuai Han; Hai-Bin Chen; Ji-Cheng Li
Journal:  Int J Oncol       Date:  2021-03-02       Impact factor: 5.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.